LADX — LadRx Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C
Brief: Cytrx Corp Enters Into Securities Purchase Agreement For $10 Mln With Healthcare-Focused Institutional Investor
Brief: Cytrx Notes Orphazyme’S Regulatory Update From The FDA On Arimoclomol For Niemann-Pick Disease Type C
Brief: Cytrx Corp - Orphazyme Announces Global Brand Name Miplyffa For Arimoclomol Ahead Of Prospective FDA And EMA Approvals
Brief: CytRx Highlights Orphazyme's Receipt Of FDA Acceptance & Priority Review Of NDA For Arimoclomol
Brief: Cytrx Corporation Highlights Orphazyme's Announcement Of Its Collaboration With The Michael Fox Foundation On Parkinson's Disease Research
Brief: CytRx Corp Says Arimoclomol Licensee Orphazyme A/S Completes Enrollment In Its Phase 3 Clinical Trial Of Arimoclomol
Brief: Delisting Of Securities Of Ftd Companies, Kaixin Auto Holdings (Warrant Only), Cytrx Corporation, And Insys Therapeutics From Nasdaq Stock Market
Brief: CytRx Corp To Commence Trading On OTCQB Venture Market
U.S. STOCKS ON THE MOVE-Pinterest, Cray, Tremont Mortgage, iQiyi
Brief: Cytrx Corporation Reports Q1 Loss Per Share $0.04
Brief: CytRx Corp Says Co Got Patent Covering Use Of Aldoxorubicin For Treatment Of Brain Cancer
Brief: Cytrx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided By Licensee Orphazyme A/S
Brief: CytRx Corp Highlights Positive Results From Phase 2/3 Clinical Trial In Niemann Pick Disease Type C (Npc)
Brief: CytRx Corporation Reports Q2 Loss Per Share $0.10
Brief: CytRx Corp Pays Off Balance Of Outstanding Debt